Our data indicated that in clinical practice, resectable ESCC patients with high levels of cyclin D1 expression, poor cell differentiation, and advanced pathological AJCC staging could be at high risk of distant metastases, thus close follow-up is needed or adjuvant therapy might be recommended. This evidence concerns the gene CCND1 and esophageal squamous cell carcinoma.